Investment firm SouthRidge Capital is pleased to announce on February 11, 2010 that its affiliated fund has closed a private equity agreement with Puramed BioScience in the amount of $7.5 million in equity financing.
“Southridge is very pleased to provide equity capital financing for this innovative market leader in the over-the-counter consumer market for alternative health remedies,” said Stephen Hicks, founding principal of Southridge LLC.
PuraMed BioScience was created to secure two unique opportunities. The first is to build a corporeal business, quickly, starting with its three core products: LipiGesic™ H (for acute relief of tension headaches) , LipiGesic™ M (for acute relief of migraine headaches) and PuraMed™ PM (for insomnia). All are safe, effective and target a very large over-the-counter (OTC) consumer market, together worth more than $2 billion in the U.S. Each individual product is unique to its class. The second opportunity is to become a household name in the alternative health remedy and highly fragmented OTC natural market by announcing an alternative remedy line for common ailments.
Southridge seeks investments in emerging growth areas, domestically and in international markets. Southridge has successfully participated in providing over $1.7 billion in capital to companies in the United States, the United Kingdom, China and Australia and well as others.
About Southridge Capital
Also known as Southridge LLC is a diversified financial holding company offering a wide range of products and services, including Investment Banking, Fund Management, Wealth Management and Business Solutions and Merchant Banking. For more information please visit www.southridgellc.com. at Southridge Capital or Southridge CapitalBlog
RSS